Europe Infertility Drugs Market Size, Share & Industry Trends Analysis Report By End User, By Distribution Channel (Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy), By Drug Class, By Country and Growth Forecast, 2022 - 2028
The Europe Infertility Drugs Market would witness market growth of 6.0% CAGR during the forecast period (2022-2028).
A chorionic gonadotropin injection typically costs USD 397.83 per vial without health insurance and USD 304.76 per vial with insurance. In addition, Bharat Serums and Vaccines Limited started a phase 3 clinical research in March 2022 to examine the safety and effectiveness of recombinant human follicle-stimulating hormone (900 IU) in female patients between the ages of 20 and 39. Moreover, a phase 3 clinical study for the ovarian stimulation drug QL1012, which is now being manufactured by Qilu Pharmaceutical Co., Ltd.
Therefore, the anticipated release of gonadotropins may promote the maintenance of dominance at the maximum growth rate during the foreseeable timeframe. The ovulation-stimulating medications for female infertility are used to treat infertile women and those with ovulation disorders. Some of the most popular medications for female infertility are clomiphene citrate, letrozole, gonadotropins, metformin, and bromocriptine.
With over 7 million predicted deaths from tobacco use in 2016, many of them happening early, and huge losses of healthy life owing to illness and disability, tobacco use has a major negative impact on health. With an estimated 209 million smokers (or 29% of the population), the European Region has the highest rate of tobacco usage in the whole globe. It is anticipated that half of the smokers will die prematurely as a consequence of their tobacco use, and tobacco use increases the risk and burden of illness overall in communities. Therefore, all of these reasons are driving the market for infertility medications in Europe.
The Germany market dominated the Europe Infertility Drugs Market by Country in 2021; thereby, achieving a market value of $321.6 million by 2028. The UK market is exhibiting a CAGR of 5.1% during (2022 - 2028). Additionally, The France market would experience a CAGR of 6.8% during (2022 - 2028).
Based on End User, the market is segmented into Women and Men. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy. Based on Drug Class, the market is segmented into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
Scope of the Study
Market Segments covered in the Report:
By End User
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook